Outcome after therapeutic lymph node dissection in patients with unknown primary melanoma site by Prens, S.P. (Sebastiaan P.) et al.
ORIGINAL ARTICLE – MELANOMAS
Outcome After Therapeutic Lymph Node Dissection in Patients
with Unknown Primary Melanoma Site
Sebastiaan P. Prens, MSc1, Augustinus P. T. van der Ploeg, MSc1, Alexander C. J. van Akkooi, MD, PhD1,
Cornelis A. G. M. van Montfort, PhD1, Albertus N. van Geel, MD, PhD1, Johannes H. W. de Wilt, MD, PhD2,
Alexander M. M. Eggermont, MD, PhD1,3, and Cornelis Verhoef, MD, PhD1
1Erasmus University Medical Center, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands; 2Radboud University
Nijmegen Medical Center, Nijmegen, The Netherlands; 3Institut de Cance´rologie Gustave Roussy, Villejuif, France
ABSTRACT
Purpose. The aim of this study was to evaluate the inci-
dence and outcome of melanoma of unknown primary site
(MUP) after therapeutic lymph node dissection (TLND) of
palpable nodal melanoma metastases. Disease-free (DFS)
and overall survival (OS) time of MUP patients were
analyzed and compared to patients undergoing a TLND for
known primary melanomas (MKP).
Methods. This single institution retrospective study ana-
lyzed 342 consecutive patients who were treated with 415
TLNDs for palpable nodal disease from 1982 to 2009.
Univariate and multivariate analyses included: MUP versus
MKP, gender, Breslow thickness, ulceration of primary
tumor, site of primary tumor, site of dissection, extracap-
sular extension, number of collected nodes, number of
positive nodes and the node positive ratio.
Results. A total of 47 MUP were identified in 342 patients
(13.7%). In univariate analysis, a trend was seen toward
better survival for MUP patients compared to MKP patients
having 5-year OS rates of 40% and 27%, respectively
(P = 0.06). Multivariate analysis for OS showed two
highly significant factors associated with worse prognosis:
extracapsular extension and N3 status (both P \ 0.001).
Two factors were associated with a significant better
prognosis: MUP (P = 0.03) and a neck dissection
(P = 0.04).
Conclusions. Patients with MUP showed a statistically
significant better OS compared to patients with melanoma
metastases from known primary tumors. Presence of
extracapsular extension and an increased number of posi-
tive nodes are statistically significantly negative prognostic
factors for OS. The absence of a primary melanoma in
stage III melanoma patients does not preclude surgery.
First presentation of palpable nodal disease in melanoma
patients still occurs in spite of early recognition programs
leading to a decrease in Breslow thickness.1 Approximately
4% to 9% of all patients presenting with melanoma are
diagnosed with palpable nodal disease, i.e., stage III dis-
ease.2,3 Patients with clinically detected and histologically
confirmed nodal melanoma metastases with no identifica-
tion of a primary site are diagnosed as patients with
melanoma of unknown primary site (MUP). In 8% to 20%
of all therapeutic lymph node dissections (TLND) for
regional metastatic melanoma, no primary tumor can be
found.4,5 Possible explanations for the absence of a primary
tumor are spontaneous regression, unidentified primary
melanoma, previous excision of what was considered a
benign lesion or a malignant transformation of an ectopic
nodal melanocyte.4,6 Whether patients with MUP have
better or worse prognosis than patients with melanoma of
known primary site (MKP) presented with nodal metasta-
ses is uncertain. Some studies suggest an improved survival
for patients with MUP compared to MKP, whereas others
report similar survival or even worse survival for MUP
patients.3–5,7
The aim of this study was to evaluate the incidence and
outcome of MUP patients after TLND for palpable nodal
disease compared to patients undergoing a TLND for pal-
pable nodal disease with a known primary tumor. Disease-
free survival (DFS) and overall survival (OS) were ana-
lyzed to identify prognostic factors for all patients who
underwent TLND.
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PATIENTS AND METHODS
Patients in this retrospective study were all treated with
TLND for palpable nodal disease between 1982 and 2009
at the Erasmus University Medical Center, Daniel den
Hoed Cancer Center, Rotterdam, the Netherlands. In 342
melanoma patients, a total of 415 TLNDs were performed.
Patients who were treated with a lymph node dissection
(LND) because of a positive sentinel node, patients who
underwent LND with an isolated limb perfusion and
patients who underwent elective LND were excluded.
There was no history of a primary melanoma and no
primary tumor could be located in 47 of 342 patients
(13.7%). The control group was formed by 295 patients
(86.3%) with a known primary tumor. The diagnosis of
unknown primary melanoma (MUP) consisted of histo-
logically confirmed nodal metastatic melanoma and the
absence of a primary tumor, confirmed after thorough
examination of the skin and unusual primary sites such as
urogenital, nasopharyngeal, or ocular.
All patient, primary and metastatic tumor characteristics
were prospectively collected and sorted in a data base.
Clinically detectable nodal disease and the absence of
visceral metastases was radiographically confirmed by
either ultrasound of the lymph node fields and/or the liver,
chest x-ray, cerebral magnetic resonance imaging, or
computed tomographic scan of the thorax and abdomen.
Surgical Technique
Four coauthors performed the majority of LNDs asses-
sed for this study (A.N.V.G., J.H.D.W., A.M.M.E. and
C.V.). Ilioinguinal dissections or deep groin dissections
included dissection of the femoral-inguinal and external
iliac nodes up to the common iliac artery (if necessary up
to the aorta bifurcation) and dissection of the obturator
nodes. Ilioinguinal dissections were performed by using
one long vertical incision in the early stage of the study
period. Two separate incisions were used in a later stage.
Sartorius muscle transposition to cover and protect the
femoral vessels was selectively performed when adjuvant
radiotherapy was to be expected and/or patient’s skin was
at risk. An axillary lymphadenectomy comprised dissection
for levels I–III. The modified radical neck consists of dis-
section of level I–V with preservation of the spinal
accessory muscle, internal jugular vein and sternocleido-
mastoid muscle. Radical neck dissections were only
performed if last mentioned structures were involved in the
tumor process. In all patients vacuum drains were placed
operatively and removed postoperatively if they produced
less than 100 ml in 24 hours. Postoperatively the treatment
protocol of all patients consisted of daily wound inspec-
tions. No pre-, peri- or postoperative antibiotic prophylaxis
was routinely given. Ilioinguinal dissection patients were
ordered 3 days of bed rest postoperatively, after which they
would be mobilized with the use of a support stocking.
Patients received low molecule weight heparin during
immobilization. The number and type of complications and
duration of hospitalization were recorded.
Adjuvant Therapy
In the later years of this study, several patients partici-
pated in the EORTC 18951, 18952 or 18991 trials. The
EORTC 18951 trial found no clinically relevant activity for
adding interleukin-2 to a chemoimmunotherapy combina-
tion of dacarbazine, cisplatin and interferon alfa (IFN-a)
2b.8 The EORTC 18952 trial evaluated the effects of
adjuvant therapy with intermediate doses of IFN-a 2b, and
did not show a survival benefit for patients in the treatment
group.9 The EORTC 18991 trial evaluated the role of long-
term treatment with pegylated IFN and found a sustained
effect on recurrence-free survival.10 Seven of 47 (14.9%)
MUP patients and 46 of 295 (15.6%) of MKP patients
participated in these trials.
Adjuvant radiotherapy was considered if narrow resec-
tion margins, excessive nodal involvement, i.e., more than
three positive lymph nodes, extracapsular extension (ECE),
or simultaneous in transit, subcutaneous or skin metastases
in the operation area were present.
Statistical Analysis
All descriptive and survival analyses were performed
assessing the 342 patients. The Fisher exact test, chi-square
test and Mann–Whitney U test were executed to determine
the differences between MUP and MKP patients. DFS was
calculated from the first dissection date to the date of first
recurrence. OS time was calculated from the dissection
date to date of death. Patients without such an event at their
last follow-up were censored at that time. Estimates were
made according to the Kaplan Meier method and compared
with the log rank score. The following factors were eval-
uated with a univariate Cox regression analysis: age,
gender, MUP, location of the affected lymph node basin,
the number of tumor positive lymph nodes, node-positive
ratio (N ratio; total affected lymph nodes/total collected
nodes), ECE and adjuvant radiotherapy. The number of
positive lymph nodes was defined by the American Joint
Committee on Cancer (AJCC) 2009 classification, i.e., N1
(one positive lymph node), N2 (two or three positive lymph
nodes) and N3 (more than three positive lymph nodes).
Multivariate analysis by Cox’s proportional hazards
regression model was performed with all variables reach-
ing a significance level of 10% in the univariate models. A
stepwise backward algorithm was used at a level of 5%
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significance to exclude factors. All statistical analyses were
performed by SPSS software (PASW 17.0.2; SPSS, Chi-
cago, IL).
RESULTS
A total of 342 patients were treated with TLND. A
melanoma of unknown primary (MUP) was diagnosed in
47 (13.7%) patients and 295 patients (86.3%) had a known
primary tumor (MKP). Two or more dissections were
performed in 59 patients making the total number of dis-
sections 415. The following types of dissections were
performed: inguinal (13%), iliac (5%), ilioinguinal (35%),
axillary (20%) and neck (28%).
Characteristics
Patient, tumor and lymph node characteristics are sum-
marized in Table 1. Age characteristics were very similar
for MUP (median 56, interquartile range [IQR]
44–66 years) and MKP (median 56, IQR 46–68 years)
patients (P = 0.75). Gender was not significantly different
between the MKP group (50% male) and MUP group (57%
male) (P = 0.38). The site and the extent of the LND
performed was not significantly different between both
groups (all P [ 0.05). Adjuvant radiotherapy was given in
17.6% of MKP patients and 29.8% of MUP patients
(P = 0.07). The mean and median follow-up for the entire
population was 36 and 19 months, respectively (IQR
9–43). The mean and median follow-up for MUP was 40
and 24 months (IQR 14–49) against 35 and 19 months for
MKP (IQR 8–42), respectively.
Complications
Of all patients, 44.4% experienced at least one compli-
cation during follow-up. Most frequent complications were
wound infection and/or skin necrosis (17.8%), seroma
(16.9%) and chronic lymph edema (12.3%). For patients
who underwent an inguinal LND, 59.1% experienced at
least one complication, while at least one complication was
found in 37.5% of patients who underwent an iliac LND, in
65.0% of patients who underwent an ilioinguinal LND, in
26.5% of patients who underwent an axillary dissection and
in 25.5% of patients who underwent a neck dissection.
Chronic lymph edema was present in 11.4% of patients
who underwent an inguinal LND, in 31.3% of patients who
underwent an iliac LND, in 24.2% of patients who
underwent an ilioinguinal LND and in 1.5% and 2.1% of
patients who underwent an axillary and neck LND,
respectively. MUP patients had at least one complication in
55.3% and chronic lymph edema was present in 12.5%.
TABLE 1 Baseline characteristics of patient, primary site, and
metastatic melanoma for patients with a known primary site (MKP,
n = 295) and patients with an unknown primary site (MUP, n = 47)
Characteristic MKP MUP P-value*
N % N %
Gender
Male 149 50.5 27 57.4
Female 146 49.5 20 42.6 0.38
Age
Median (IQR) 56 (44–66) 56 (46–68) 0.75
Site of primary
Head/neck 61 20.7 – –
Trunk 88 29.8 – –
Extremity 141 47.8 – –
Other 5 1.7 – – NA
Breslow thickness
T1 35 11.9 – –
T2 80 27.1 – –
T3 72 24.4 – –
T4 75 25.4 – –
Missing 33 11.2 – – NA
Histology
NM 89 30.2 – –
SSM 64 21.7 – –
Other 17 5.8 – –
Missing 125 42.4 – – NA
Cark level
II 13 4.4 – –
III 69 23.4 – –
IV 115 39.0 – –
V 34 11.5 – –
Missing 64 21.7 – – NA
Ulceration
Absent 217 73.6 – –
Present 78 26.4 – – NA
Site of TLND
Inguinal 39 13.2 5 10.6
Iliac 15 5.1 1 2.1
Ilioinguinal 103 34.9 17 36.2
Axillary 58 19.7 10 21.3
Neck 80 27.1 14 29.8 0.89
Nr. of harvested nodes
Median (IQR) 16 (11–26) 17 (12–28) 0.55
Nr. of positive nodes
Median (IQR) 2 (1–4) 1 (1–7) 0.71
AJCC staging
N1 124 42.0 24 51.1
N2 86 29.2 6 12.8
N3 70 23.7 14 29.8
Missing 15 5.8 3 6.4 0.07
Outcome of Unknown Primary Melanoma
MKP patients had at least one complication in 55.6% and
chronic lymph edema was present in 12.8%.
The median duration of hospitalization was 5 days (IQR
3–8 days) for both MUP and MKP patients (P = 0.484).
Survival
Univariate analyses demonstrated that the following
factors statistically significantly affected DFS: site of dis-
section, number of positive nodes, node positive ratio, ECE
(Table 2). Multivariate analyses for DFS showed three sig-
nificant prognostic factors: N2 (P = 0.04), N3 (P \ 0.001)
and ECE (P = 0.004) (Table 3). Gender, age, the number of
collected lymph nodes, primary site, Clark level, histology
of the primary, MUP and adjuvant radiotherapy were not
statistically significant. Hazard ratios and P-values of all
analyzed factors are summarized in Tables 2 and 3.
As for OS, ulceration, site of dissection, node positive
ratio, number of positive nodes, ECE and MUP were
statistically significant prognostic factors (Table 2).
Ulceration was not known for MUP patients and not
included in multivariate analyses. Multivariate analysis for
OS revealed two highly significant factors associated with
worse prognosis: the presence of ECE and N3 status (both
P \ 0.001). Two factors were associated with significant
better prognosis: MUP (P = 0.03) and neck dissections
(P = 0.04) (Table 3).
The estimated 5-year DFS rates for ECE were an esti-
mated 12% when present and 26% when absent
(P \ 0.001). For nodal status, 5-year DFS rates were 31%,
17% and 9% for the respective N1, N2 and N3 categories
TABLE 1 continued
Characteristic MKP MUP P-value*
N % N %
LN ratio (%)
Median (IQR) 11.6 (6.3–26.3) 8.2 (4.8–32.3) 0.38
ECE
No 205 69.5 29 61.7
Yes 90 31.5 18 38.3 0.31
Adjuvant radiotherapy
No 243 82.4 33 70.2
Yes 52 17.6 14 29.8 0.07
Nr. of TLND performed
1 295 81.7 47 87.0
[1 66 18.3 7 13.0 0.88
NM nodular melanoma, SSM superficial spreading melanoma, LN
lymph node, NA not applicable
* P values were calculated by Fisher exact test, chi-square test, or
Mann-Whitney U-test
TABLE 2 Univariate analyses of prognostic factors for DFS and OS
Variable DFS OS
HR 95% CI P-value HR 95% CI P-value
Gender
Female 1 1
Male 1.03 0.80–1.33 0.81 1.22 0.94–1.59 0.13
Age
B50 years 1 1
[50 years 0.94 0.73–1.21 0.63 1.01 0.77–1.32 0.94
Site of primary lesion
Extremity 1 1
Head/neck 0.77 0.53–1.11 0.16 0.81 0.55–1.18 0.26
Trunk 1.34 0.99–1.82 0.06 1.30 0.95–1.78 0.11
Other 0.54 0.22–2.20 0.54 0.49 0.11–1.97 0.31
Unknown 0.73 0.63–1.38 0.73 0.70 0.45–1.08 0.10
MUP
No 1 1
Yes 0.92 0.64–1.31 0.63 0.68 0.45–1.03 0.07
Breslow
T1 1 1
T2 1.37 0.85–2.21 0.20 1.54 0.91–2.63 0.11
T3 1.78 1.10–2.89 0.02 1.80 1.05–3.07 0.03
T4 1.18 0.72–1.94 0.51 1.62 0.95–2.76 0.08
MUP 1.21 0.72–2.06 0.47 1.08 0.59–1.97 0.81
Histology
SSM 1 1
NM 1.07 0.74–1.55 0.73 1.10 0.75–1.61 0.64
MUP 0.91 0.59–1.41 0.68 0.71 0.44–1.15 0.16
Other 0.70 0.36–1.39 0.31 0.94 0.49–1.82 0.85
Clark level
II 1 1
III 0.88 0.46–1.69 0.70 1.16 0.55–2.45 0.70
IV 0.96 0.51–1.80 0.90 1.11 0.54–2.29 0.78
V 0.85 0.41–1.73 0.64 1.12 0.51–2.51 0.77
MUP 0.83 0.42–1.64 0.60 0.79 0.36–1.74 0.55
Ulceration
Absent 1 1
Present 1.21 0.90–1.63 0.2 1.48 1.10–1.99 0.01
Site of TLND
Inguinal 1 1
Iliac 0.97 0.47–1.98 0.93 0.96 0.49–1.87 0.90
Ilioinguinal 0.76 0.50–1.14 0.18 0.71 0.47–1.07 0.10
Axillary 1.14 0.73–1.76 0.57 1.06 0.68–1.67 0.78
Neck 0.63 0.41–0.97 0.04 0.61 0.39–0.94 0.03
No. of
collected
nodes
1.00 0.99–1.01 0.54 1.00 0.99–1.01 0.65
AJCC staging
N1 1 1
N2 1.34 0.98–2.50 0.07 1.33 0.96–1.84 0.09
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(P \ 0.001). The 5-year DFS rate for MKP patients was
21%, while the 5-year DFS rate for MUP patients was 25%
(P = 0.619).
Absence of ECE demonstrated a 5-year OS of 36%
compared to 15% when present (P \ 0.001) (Fig. 1a). The
estimated 5-year OS rates for the different categories of
nodal status (N1, N2 and N3) were 36%, 30% and 16%,
respectively (P \ 0.001) (Fig. 1b). The 5-year estimated
Kaplan–Meier OS rate for MUP versus MKP showed a
trend toward a better survival for MUP at 43% vs. 27% for
MKP, respectively (P = 0.06) (Fig. 1C).
DISCUSSION
In this retrospective study, 342 melanoma patients
treated with a total of 415 TLND for palpable lymph nodes
metastases were analyzed. Outcome of melanoma patients
with an unknown primary site (MUP) were compared with
patients with a known site of the primary melanoma lesion
(MKP). After multivariate analysis, a statistically signifi-
cant OS benefit was found for patients with MUP over
MKP patients. Five-year OS rates were 43% for MUP
patients and 27% for MKP patients (P = 0.03).
Cormier et al. demonstrated a significant survival benefit
for 71 MUP patients in a multivariate Cox proportional
hazard model when adjusted for nodal status, dissection
site, age, gender and adjuvant therapy as well (P = 0.006).
The 5-year OS rates were 55% and 42% for MUP versus
MKP, respectively, with a median follow-up of
92 months.5 Lee et al. demonstrated similar results with
5-year OS rates of 55% for MUP patients (N = 262) and
44% for MKP patients (N = 1309), with a median follow
up of 36 months. Again MUP was identified as a signifi-
cant prognostic factor in multivariate analysis
(P = 0.0001).4 Where previous mentioned studies revealed
a small increased 5-year OS rate compared to our results,
Chang et al. reported similar 5-year OS rates for both
groups; 46% for MUP and 49% for MKP.3
All the above mentioned studies demonstrated higher
5-year OS rates for MKP (42%–49%) compared to our
results (27%). No statistically significant differences were
found in patient and tumor characteristics between all
studies.3–5 A reason for the worse survival of MKP patients
in the present study might be the short median follow-up.
Moreover, a tertiary referral center might perform surgery
in patients with more advanced cases which might lead to
worse survival.
A possible hypothesis for the survival benefit seen in
MUP patients is an endogenous immune response, which
also might have caused regression of the primary lesion.
Interleukin-2 and IFN-a have shown some therapeutic
benefit, supposedly by enhancing antitumor immune
responses.10–12 In a small study Moschos et al. treated 20
patients with stage IIIB and IIIC disease with neoadjuvant
high-dose IFN-a 2b. Three were diagnosed with MUP and
demonstrated no evidence of disease after 7, 9 and
10 months, respectively.13 Furthermore, cytoreductive
surgery (complete metastasectomy) revealed a long-term
clinical benefit that depended on the host’s immune
response to a surgical reduction in tumor burden.14 Causes
for the effectiveness of these therapies in MUP patients
might be the favorable patients’ immune system. Unfor-
tunately, no specific data are available to prove a difference
between survival of MUP and MKP patients receiving any
form of immunotherapy.
TABLE 3 Multivariate analyses of prognostic factors in all patients
(n = 342) for DFS and OS
Characteristic Variable N HR 95% CI P
DFS
AJCC staging N1 148 1
N2 92 1.40 1.02–1.93 0.04
N3 84 2.08 1.47–2.94 \0.001
ECE No 234 1
Yes 108 1.57 1.16–2.12 0.004
OS
ECE No 285 1
Yes 130 1.69 1.25–2.28 0.001
MUP No 47 1
Yes 295 0.62 0.40–0.96 0.03
AJCC staging N1 148 1
N2 92 1.28 0.92–1.79 0.15
N3 84 1.80 1.28–2.52 0.001
Dissection type Inguinal 44 1
Axillary 68 0.74 0.47–1.16 0.19
Neck 94 0.61 0.38–0.97 0.04
HR hazard ratio, CI confidence interval
TABLE 2 continued
Variable DFS OS
HR 95% CI P-value HR 95% CI P-value
N3 1.90 1.39–2.58 \0.001 1.97 1.43–2.72 \0.001
LN ratio 2.35 1.51–3.64 \0.001 2.83 1.80–4.45 \0.001
ECE
Absent 1 1
Present 1.60 1.23–2.08 \0.001 1.83 1.39–2.40 \0.001
Adjuvant radiotherapy
No 1 1
Yes 1.13 0.83–1.53 0.45 1.18 0.85–1.63 0.33
HR hazard ratio, CI confidence interval, SSM superficial spreading
melanoma, NM nodular melanoma, LN lymph node
Outcome of Unknown Primary Melanoma
The rate of MUP in patients treated with TLND for
palpable nodal disease was 13.7% in our institute (47 of
342). This is in line with other studies. In the study per-
formed by Rutkowski et al., the rate was 12.8%.15 Lee et al.
demonstrated a MUP rate of 16.7%, while the study per-
formed by Cormier et al. had a MUP rate of 13.2%.4,5
Lymph node status and ECE are important statistically
significant prognostic factors for OS, which has been
demonstrated in several studies.4,15–18 A previous study
from our group demonstrated that ECE was the most
important prognostic factor for OS after TLND.16 A recent
MUP study by Rutkowski et al also revealed ECE and
lymph node status as significant factors for OS.15 Balch
et al. found several significant prognostic factors for stage
III melanoma such as nodal micrometastases, number of
tumor-containing lymph nodes, Breslow thickness, patient
age, ulceration, site of the primary and primary mitotic
rate. Unfortunately MUP and ECE were not analyzed in
their study.17 Disease of patients with metastatic melanoma
from an unknown primary site, arising in lymph nodes,
skin, or subcutaneous tissues, was clarified to be catego-
rized as stage III rather than stage IV.19
The fact that patients treated with neck dissections
had a survival benefit versus inguinal dissections is coun-
terintuitive because head/neck melanomas are associated
with worse prognosis.2,17,20 It may be a chance finding as
the minimal significant difference (P = 0.04) could be
explained by the small sample size, the difference in age
(median 54 vs. 62 years) and percentage of ECE (24.4%
vs. 37.1%).
Comparing MUP patients with MKP patients stratified
by Breslow thickness as T1, T2, T3 and T4 showed
increased hazard ratios for T2 (hazard ratio = 1.54), T3
(hazard ratio = 1.80) and T4 (hazard ratio = 1.62) versus
a T1 tumor. MUP patients showed nearly the same hazard
ratio (hazard ratio = 1.08) as patients with T1 tumors at
univariate analysis. Increasing Clark level was of little
significance for OS, as did the MUP patients with unknown
Clark scores. Patients with ulcerated primaries had signif-
icant worse OS (P = 0.01) compared to the unknown
group. Also MUP patients have a survival benefit com-
pared to patients with a primary tumor located on an
extremity or trunk. It was previously suggested that MUP
patients had a worse prognosis compared to patients with
known primary tumors.3 These data suggest at least that
MUP is not a significant negative prognostic factor com-
pared to some stage III melanoma patients with known
primary tumor characteristics.
A recent study in the Netherlands by Koomen et al.
demonstrated that the incidence of noncutaneous melanoma
a b
c
FIG. 1 OS for (a) ECE,
(b) number of positive lymph
nodes according to AJCC
staging system, and (c) MUP
and MKP
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is very rare.21 Therefore, the value of nasopharyngeal
examination is doubtful and could be ignored when a
patient presents with a palpable lymph node without a
known primary tumor. A thorough physical examination in
order to locate a primary tumor is still recommended. Also
close examination of the skin of the drainage area of the
metastatic lymph node could be considered in order to
identify a regressive primary lesion.22
In conclusion, this study showed the presence of ECE,
an increased number of positive nodes and patients with
MKP as statistically significantly negative prognostic fac-
tors for OS. Patients with melanoma of an unknown
primary site showed a statistically significantly better OS
after multivariate analysis compared to patients with mel-
anoma metastases from known primary tumors. Melanoma
patients with palpable nodal disease and a MUP should be
classified as stage III disease. The absence of a primary
melanoma in stage III melanoma patients does not preclude
surgery.
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